VivoSim Labs, Inc. (VIVS)
NASDAQ: VIVS · Real-Time Price · USD
1.360
+0.020 (1.49%)
At close: May 22, 2026, 4:00 PM EDT
1.359
-0.001 (-0.10%)
After-hours: May 22, 2026, 7:43 PM EDT
VivoSim Labs Revenue
In the fiscal year ending March 31, 2025, VivoSim Labs had annual revenue of $144.00K with 32.11% growth. VivoSim Labs had revenue of $26.00K in the quarter ending December 31, 2025, a decrease of -13.33%.
Revenue (ttm)
$144.00K
Revenue Growth
+32.11%
P/S Ratio
27.72
Revenue / Employee
$10,143
Employees
14
Market Cap
3.94M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 144.00K | 35.00K | 32.11% |
| Mar 31, 2024 | 109.00K | - | - |
| Dec 31, 2023 | 109.00K | -261.00K | -70.54% |
| Mar 31, 2023 | 370.00K | - | - |
| Dec 31, 2022 | 370.00K | -1.13M | -75.33% |
| Mar 31, 2022 | 1.50M | - | - |
| Dec 31, 2021 | 1.50M | - | - |
| Mar 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Mar 31, 2020 | 2.20M | - | - |
| Dec 31, 2019 | 2.20M | -895.00K | -28.96% |
| Mar 31, 2019 | 3.09M | - | - |
| Dec 31, 2018 | 3.09M | -1.51M | -32.85% |
| Mar 31, 2018 | 4.60M | - | - |
| Dec 31, 2017 | 4.60M | 373.00K | 8.82% |
| Mar 31, 2017 | 4.23M | - | - |
| Dec 31, 2016 | 4.23M | 2.75M | 185.23% |
| Mar 31, 2016 | 1.48M | - | - |
| Dec 31, 2015 | 1.48M | 912.00K | 159.72% |
| Mar 31, 2015 | 571.00K | 192.00K | 50.66% |
| Mar 31, 2014 | 379.00K | -818.00K | -68.34% |
| Dec 31, 2012 | 1.20M | 228.00K | 23.53% |
| Dec 31, 2011 | 969.00K | - | - |
| Dec 31, 2010 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| 60 Degrees Pharmaceuticals | 1.31M |
| AIM ImmunoTech | 94.00K |
| Cardio Diagnostics Holdings | 16.57K |
| Azitra | 7.50K |
| Soligenix | 2.34K |
VIVS News
- 27 days ago - VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing - GlobeNewsWire
- 7 weeks ago - VivoSim Announces Pricing of up to a $4 Million Public Offering - GlobeNewsWire
- 2 months ago - VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs - GlobeNewsWire
- 2 months ago - VivoSim appoints Arumugham Raghunathan as VP, global sales - TheFly
- 2 months ago - VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales - GlobeNewsWire
- 3 months ago - VivoSim to debut antibody drug conjugate data at SOT meeting - TheFly
- 3 months ago - VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego - GlobeNewsWire
- 4 months ago - VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China - GlobeNewsWire